IGC · IGC Pharma, Inc.
$0.30
0.00 (-1.20%)
At close · Aug 24
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company assesses and determines its ability to continue as a going concern in accordance with the provisions of ASC Subtopic 205-40, "Presentation of Financial Statements—Going Concern", which requires the Company to evaluate whether there are conditions or events that raise substantial doubt about its ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$31.84M
Shares
103.38M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.31
Open$0.29
Day$0.28–0.31
52W close$0.24–0.47
Avg vol 30d685K
Short int542K · 0.5% float · 1.7d
Short vol40%
DataJan 2020–Aug 2026
Filing10-Q · Aug 14
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 14, 2026
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.1 · calm
Equity put/call 0.51
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+5%
above
Price vs 50-day avg
+14%
above
RSI (14)
67
neutral
MACD trend
Positive
52-week position
30%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+18%
trailing
6-month return
+14%
trailing
YTD return
+10%
this year
Relative strength
+3%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Accumulating
+3% holders QoQ · +7 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.52% of float · ▲ +39.2% MoM · 1.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
36 holders — near 3-yr high, broad support
Squeeze score
52
elevated · 0–100
Fundamentals
Revenue growth
−6%
Y/Y
Gross margin
49%
contracting
EPS growth
+59%
Y/Y
Free cash flow
$-4.9M
Balance sheet
$499.0K
net cash
Quant / Vol
risk profile
Volatility
56%
annualized · 1-yr
Max drawdown
−49%
past year
ATR
4.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+5%
Bullish
Price vs 50-day avg
+14%
Bullish
RSI (14)
67
Neutral
MACD trend
Positive
Bullish
52-week position
30%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Accumulating
+3% holders QoQ · +7 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.52% of float · ▲ +39.2% MoM · 1.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
36 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $0
Now $0 · 30%
Range high $0
vs 200-day avg +5%
vs 50-day avg +14%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IGC
this stock
IGC Pharma, Inc.
|
$31.84M | +10.0% | +39.5% | — | 0.5% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.91B | +20.9% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$85.87B | +8.1% | +20.8% | 20.7 | 3.3% |
|
ARGX
Argenx SE
|
$64.66B | +23.6% | — | — | 2.1% |
|
CSLLY
Csl Ltd
|
$57.97B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IGC | +2.7% | +18.5% | +14.1% | +23.2% | +10.0% |
| SPY | -1.4% | +3.6% | +11.6% | +2.5% | +12.3% |
| vs SPY | +4.0% | +14.8% | +2.5% | +20.7% | -2.3% |